Advancing the Future of Long Non-Coding RNA (lncRNA) Medicine
Developing first-in-class therapies to precisely target disease-driving long non-coding RNAs (lncRNAs) in oncology and beyond
SCIENCE
lncRNAs: A Vast and Largely Untapped Therapeutic Landscape
Traditional drug development has focused on the ~2% of the genome encoding proteins, leaving ~98% — largely non-coding RNAs, including lncRNAs.
Predominantly uncharacterised, yet a handful of lncRNAs linked to major human diseases.
No approved drugs target lncRNAs — the opportunity to create next frontier first-in-class lncRNA medicine.
APPROACH
Turning lncRNA Biology into Precision Medicines
We employ systematic strategies and integrated proprietary platforms to discover, prioritise, and functionally characterise disease-relevant lncRNAs, and to target them with precision and effectiveness.
AMRQ-ARCANA
01
An advanced computational engine that discovers and prioritises disease-relevant lncRNAs.
AMRQ TARGET ID ATLAS
02
A curated atlas of functionally validated and high-confidence disease-relevant lncRNA targets.
AMRQ Drug Discovery (DD)
03
A dedicated drug discovery and development program focused on creating effective therapies that target pathogenic lncRNAs.
Amaroq is Focused on High-Quality Programs for Oncology First
Oncology programs are prioritised based on high unmet need with best-in-class potential geared towards reliable delivery to specific organs, tissues and cells of interest.
PIPELINE
ONCOLOGY
Undisclosed Target 1
ONCOLOGY
Undisclosed Target 2
Core Team Members
Team members
Dr Rachael Brake
CEO
ex-Takeda Oncology, Amgen, Corbus, Zephyr AI, Abdera Therapeutics; 25+ years of experience in building companies, franchises, and teams across multinational pharma and emerging biotech, Rachael has operated at every stage of the biotech lifecycle from early-stage platform science through late-stage clinical development, regulatory approval, and commercialization. She has experience spanning both public and private capital markets, with a track record of value creation reflected in leading teams to successful IND candidates and regulatory drug approvals, millions of dollars in fundraising, as well as having foundational roles in now, two different billion-dollar company acquisitions.
Board of Directors
Board of Directors
Dr Rachael Brake
Board Director
ex-Takeda Oncology, Amgen, Corbus, Zephyr AI, Abdera Therapeutics; 25+ years of experience in building companies, franchises, and teams across multinational pharma and emerging biotech, Rachael has operated at every stage of the biotech lifecycle from early-stage platform science through late-stage clinical development, regulatory approval, and commercialization. She has experience spanning both public and private capital markets, with a track record of value creation reflected in leading teams to successful IND candidates and regulatory drug approvals, millions of dollars in fundraising, as well as having foundational roles in now, two different billion-dollar company acquisitions.
Our partners
& investors
Our partners & investors
